TY - JOUR
T1 - Costs and resource use associated with community-dwelling patients with Alzheimer's disease in Japan
T2 - Baseline results from the prospective observational GERAS-J Study
AU - Nakanishi, Miharu
AU - Igarashi, Ataru
AU - Ueda, Kaname
AU - Brnabic, Alan J.M.
AU - Treuer, Tamas
AU - Sato, Masayo
AU - Kahle-Wrobleski, Kristin
AU - Meguro, Kenichi
AU - Yamada, Masahito
AU - Mimura, Masaru
AU - Arai, Heii
N1 - Funding Information:
We firstly wish to thank the participating patients and their caregivers, site investigators, and study personnel who participated in this study. The authors would like to thank Drs. Joel Raskin and Catherine Reed, both of Eli Lilly and Company, for protocol review and consultancy. This study was supported by Eli Lilly and Company, and medical writing and editorial assistance was provided by Lori Kornberg, PhD, and Antonia Baldo, BA, who are full-time employees of Syneos Health (Raleigh, NC).
Publisher Copyright:
© 2020 - IOS Press and the authors. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background: As the Japanese population ages, caring for people with Alzheimer's disease (AD) dementia is becoming a major socioeconomic issue. Objective: To determine the contribution of patient and caregiver costs to total societal costs associated with AD dementia. Methods: Baseline data was used from the longitudinal, observational GERAS-J study. Using the Mini-Mental State Examination (MMSE) score, patients routinely visiting memory clinics were stratified into three groups based on AD severity. Health care resource utilizationwas recorded using the Resource Utilization in Dementia questionnaire. Total monthly societal costs were estimated using Japan-specific unit costs of services and products (patient direct health care use, patient social care use, and informal caregiving time). Uncertainty around mean costs was estimated using bootstrapping methods. Results: Overall, 553 community-dwelling patients withADdementia (28.3% mild[MMSE21-26], 37.8% moderate[MMSE 15-20], and 34.0% moderately severe/severe [MMSE < 14]) and their caregivers were enrolled. Patient characteristics were: mean age 80.3 years, 72.7% female, and 13.6% living alone. Caregiver characteristics were: mean age 62.1 years, 70.7% female, 78.8% living with patient, 49.0% child of patient, and 39.2% sole caregiver. Total monthly societal costs of AD dementia (Japanese yen) were: 158,454 (mild), 211,301 (moderate), and 294,224 (moderately severe/severe). Informal caregiving costs comprised over 50% of total costs. Conclusion: Baseline results of GERAS-J showed that total monthly societal costs associated with AD dementia increased with AD severity. Caregiver-related costs were the largest cost component. Interventions are needed to decrease informal costs and decrease caregiver burden.
AB - Background: As the Japanese population ages, caring for people with Alzheimer's disease (AD) dementia is becoming a major socioeconomic issue. Objective: To determine the contribution of patient and caregiver costs to total societal costs associated with AD dementia. Methods: Baseline data was used from the longitudinal, observational GERAS-J study. Using the Mini-Mental State Examination (MMSE) score, patients routinely visiting memory clinics were stratified into three groups based on AD severity. Health care resource utilizationwas recorded using the Resource Utilization in Dementia questionnaire. Total monthly societal costs were estimated using Japan-specific unit costs of services and products (patient direct health care use, patient social care use, and informal caregiving time). Uncertainty around mean costs was estimated using bootstrapping methods. Results: Overall, 553 community-dwelling patients withADdementia (28.3% mild[MMSE21-26], 37.8% moderate[MMSE 15-20], and 34.0% moderately severe/severe [MMSE < 14]) and their caregivers were enrolled. Patient characteristics were: mean age 80.3 years, 72.7% female, and 13.6% living alone. Caregiver characteristics were: mean age 62.1 years, 70.7% female, 78.8% living with patient, 49.0% child of patient, and 39.2% sole caregiver. Total monthly societal costs of AD dementia (Japanese yen) were: 158,454 (mild), 211,301 (moderate), and 294,224 (moderately severe/severe). Informal caregiving costs comprised over 50% of total costs. Conclusion: Baseline results of GERAS-J showed that total monthly societal costs associated with AD dementia increased with AD severity. Caregiver-related costs were the largest cost component. Interventions are needed to decrease informal costs and decrease caregiver burden.
KW - Alzheimer's disease
KW - cost and cost analysis
KW - Japan
KW - observational study
UR - http://www.scopus.com/inward/record.url?scp=85081989229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081989229&partnerID=8YFLogxK
U2 - 10.3233/JAD-190811
DO - 10.3233/JAD-190811
M3 - Article
C2 - 31985460
AN - SCOPUS:85081989229
SN - 1387-2877
VL - 74
SP - 127
EP - 138
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 1
ER -